Mibi (Copper Tetramibi Tetrafluoroborate)

The exact pharmacological action is not fully defined. The compound is believed to function as a copper‑based complex that can interact with cellular enzymes and oxidative pathways, potentially disrupting microbial metabolism or tumor cell growth by altering redox balance and chelating intracellular copper ions.

Dosing of Mibi is determined by the prescribing clinician based on the specific study protocol or therapeutic context. No standardized dosage regimen is publicly available, and the prescriber should follow the guidance provided in the relevant clinical trial or investigational use documentation.

Safety data for Copper Tetramibi Tetrafluoroborate in pregnancy or lactation are insufficient. Use during pregnancy or breastfeeding should only be considered if the potential benefit outweighs the possible risk, and it should be decided by a qualified healthcare professional.

To request Mibi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Mibi is a copper‑tetramibi complex, a class with limited publicly disclosed data. Compared with other copper‑based agents, its investigational status means fewer clinical data are available, and its safety and efficacy profile remain under evaluation in early‑stage studies.

Mibi should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken, and it should be kept in its original packaging to maintain stability until administration.

Mibi is supplied as an injectable solution for intravenous use. Administration is performed by a qualified healthcare professional in a clinical setting, following aseptic technique and the specific infusion protocol outlined in the study or prescribing information.

Serious risks reported in early observations include anaphylaxis, severe hypotension, and significant elevations in liver enzymes. Patients should be monitored closely for signs of allergic reaction, blood pressure changes, and hepatic function during and after infusion.

Mibi is contraindicated in individuals with known hypersensitivity to copper compounds or any component of the formulation. It should also be avoided in patients with uncontrolled severe liver disease, severe renal impairment, or in situations where the risk of serious allergic reactions cannot be managed.